• Stayble Science
  • Market Potential
  • The Vision
  • Investor Relations
  • Upcoming Events
  • Our Team
  • How To Contact Us
  • sv
  • en
Stayble Therapeutics
  • Stayble Science
  • Market Potential
  • The Vision
  • Investor Relations
  • Upcoming Events
  • Our Team
  • How To Contact Us
  • sv
  • en

Financial Information

  1. Overview
  2. Press releases
  3. Financial Reports
  4. IPO 2020
  5. Rights Issue 2021
  6. Financial Calendar
  7. The Share
    • Owners
    • PDMR transactions
  8. Corporate Governance
    • Board of Directors
    • Management
    • Articles of association
    • General Meetings
  9. Presentations
  10. Previous issues
    • Warrant TO1
  11. IR contact

IR Contact

M. Sc, CEO. Andreas Gerward

Andreas has during the last 7 years worked with pharmaceutical development in smaller companies. Since joining Stayble as the CEO in 2014 Andreas has developed the company from selection of the candidate drug through preclinical development and successful clinical trials. Andreas has an engineering background and a master’s in economics and Venture Creation from Chalmers University of Technology.

andreas.gerward@stayble.se +46 (0)730 808 397
Back

IR Contact

M. Sc, CEO. Andreas Gerward

Andreas has during the last 7 years worked with pharmaceutical development in smaller companies. Since joining Stayble as the CEO in 2014 Andreas has developed the company from selection of the candidate drug through preclinical development and successful clinical trials. Andreas has an engineering background and a master’s in economics and Venture Creation from Chalmers University of Technology.

andreas.gerward@stayble.se +46 (0)730 808 397
Stayble Therapeutics
CONTACT

Medicinaregatan 8A,
413 90 Göteborg
info@stayble.se

Menu
  • Stayble Science
  • Market Potential
  • The Vision
  • Investor Relations
  • Upcoming Events
  • Our Team
  • How To Contact Us
STAYBLE THERAPEUTICS

Stayble Therapeutics is a Swedish life science company developing an injectable treatment against chronic low back pain triggered by disc degeneration. Stayble Therapeutics currently plans to launch a multinational clinical phase 2b study in 2020.

To top

We use cookies to improve the user experience on Stayble Therapeutics. Read more about Cookies

Approve